Multiple studies [6–11] have examined the extent to which Ki67 IHC correlates with the 21-gene breast cancer recurrence score (RS) assay, which is included in NCCN and ASCO guidelines for selecting HR+HER2− breast cancer patients for chemotherapy [12, 13]. This evidence concerns the gene ERBB2 and breast cancer.